Wize Pharma retains Lighthouse BioPartners for LO2A

Wize Pharma, a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders has announced that it has retained Lighthouse BioPartners, LLC a US-based firm specialized in partnering and financial advisory services for life sciences companies worldwide, to assist in sourcing and consummating deals for further development and commercialization of Wize's lead asset, LO2A a prescription eye drop product for the treatment of dry eye syndrome (DES), a $3.7 billion global market. 

Wize's CEO Noam Danenberg said, "The ophthalmic treatment market has recently seen a string of high value M&A and licensing deals. We believe our lead asset, LO2A, has substantial commercial potential in several geographic territories. Having recently completed a successful Phase II study of LO2A in the symptomatic treatment of DES in patients with moderate to severe conjunctivochalasis (CCh), we look ahead to announcing top line results in our Phase IV study of LO2A for symptomatic improvement of DES in patients with Sjögren's Syndrome in the first quarter of 2020. We are pleased to work with Lighthouse BioPartners to accelerate commercialization.”

Lighthouse BioPartners works with big pharma, specialty pharma, and biotech companies of all stages of development on in-licensing, out-licensing, and partnership transactions.

Per the agreement, Lighthouse BioPartners will both engage in new negotiations for Wize as well as manage existing leads and interest in LO2A from potential pharma partners.